Table 1.
Study Participant Characteristics
| TAK | GCA | HLD | |
|---|---|---|---|
| Number of Patients | 22 | 29 | 37 |
| Age in years, median (range) | 34 (18-52) | 71 (54-85) | 63 (59-67) |
| BMI, Kg/m2 | 27.4 (18.5-49.7) | 26.9 (20.9-39.2) | 27.1 (25.2-29.8) |
| SBP, mmHg, median (range) | 115.5 (83-132) | 133 (98-164) | 130 (121.5-136) |
| DBP, mmHg, median (range) | 63.5 (44-78) | 62 (48-81) | 73 (65-79.5) |
| Smoker, n (%) | 0 | 0 | 16 (43) |
| HTN requiring antihypertensive medication, n (%) | 12 (55) | 17 (59) | NA |
| Statin, n (%) | 5 (23) | 7 (24) | 32 (86) |
| Anti- Diabetic medication n (%) | 1 (4) | 1 (3.4) | 0 (0) |
| Glucocorticoid, n (%) | 13 (59) | 19 (66) | NA |
| DMARD, n (%) | 14 (64) | 13 (45) | NA |
| Fasting serum glucose, mg/dl | 89.5 (68-154) | 93 (76-140) | 89 (84-97) |
| C-Reactive protein, mg/L | 4.9 (0.6-89.1) | 6.2 (0.2-127.9) | NA |
| ESR, mm/hr | 18.5 (2-55) | 16 (2-105) | NA |
| Active vascular FDG PET uptake, n (%) | 10 (45) | 19 (66) | NA |
| Physician assessment of active disease, n (%) | 10 (45) | 10 (35) | NA |
| Disease duration in years, median (range) | 12 (1.5- 38) | 1.5 (0.4-10.5) | NA |
N = number; SBP = systolic blood pressure; DBP = diastolic blood pressure; htn = hypertension; DMARD = disease modifying antirheumatic drug; FDG-PET = fluorodeoxyglucose positron emission tomography; NA = not assessed.